High-risk prostate cancer treated with a stereotactic body radiation therapy boost following pelvic nodal irradiation

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Lischalk, Jonathan W.
    • Other Affiliation: New York University Langone Hospital - Long Island
  • Akerman, Meredith
    • Other Affiliation: New York University Langone Health
  • Repka, Michael C.
    • Affiliation: School of Medicine, Department of Radiation Oncology
  • Sanchez, Astrid
    • Other Affiliation: New York University Langone Hospital - Long Island
  • Mendez, Christopher
    • Other Affiliation: New York University Langone Hospital - Long Island
  • Santos, Vianca F.
    • Other Affiliation: New York University Langone Hospital - Long Island
  • Carpenter, Todd
    • Other Affiliation: New York University Langone Hospital - Long Island
  • Wise, David
    • Other Affiliation: New York University Langone Health - Manhattan
  • Corcoran, Anthony
    • Other Affiliation: New York University Langone Hospital - Long Island
  • Lepor, Herbert
    • Other Affiliation: New York University Grossman School of Medicine
  • Katz, Aaron
    • Other Affiliation: New York University Langone Hospital - Long Island
  • Haas, Jonathan A.
    • Other Affiliation: New York University Langone Hospital - Long Island
Abstract
  • Purpose Modern literature has demonstrated improvements in long-term biochemical outcomes with the use of prophylactic pelvic nodal irradiation followed by a brachytherapy boost in the management of high-risk prostate cancer. However, this comes at the cost of increased treatment-related toxicity. In this study, we explore the outcomes of the largest cohort to date, which uses a stereotactic body radiation therapy (SBRT) boost following pelvic nodal radiation for exclusively high-risk prostate cancer. Methods and materials A large institutional database was interrogated to identify all patients with high-risk clinical node-negative prostate cancer treated with conventionally fractionated radiotherapy to the pelvis followed by a robotic SBRT boost to the prostate and seminal vesicles. The boost was uniformly delivered over three fractions. Toxicity was measured using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Oncologic outcomes were assessed using the Kaplan–Meier method. Cox proportional hazard models were created to evaluate associations between pretreatment characteristics and clinical outcomes. Results A total of 440 patients with a median age of 71 years were treated, the majority of whom were diagnosed with a grade group 4 or 5 disease. Pelvic nodal irradiation was delivered at a total dose of 4,500 cGy in 25 fractions, followed by a three-fraction SBRT boost. With an early median follow-up of 2.5 years, the crude incidence of grade 2+ genitourinary (GU) and gastrointestinal (GI) toxicity was 13% and 11%, respectively. Multivariate analysis revealed grade 2+ GU toxicity was associated with older age and a higher American Joint Committee on Cancer (AJCC) stage. Multivariate analysis revealed overall survival was associated with patient age and posttreatment prostate-specific antigen (PSA) nadir. Conclusion Utilization of an SBRT boost following pelvic nodal irradiation in the treatment of high-risk prostate cancer is oncologically effective with early follow-up and yields minimal high-grade toxicity. We demonstrate a 5-year freedom from biochemical recurrence (FFBCR) of over 83% with correspondingly limited grade 3+ GU and GI toxicity measured at 3.6% and 1.6%, respectively. Long-term follow-up is required to evaluate oncologic outcomes and late toxicity.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
License
  • Attribution 4.0 International
Journal title
  • Frontiers in Oncology
Journal volume
  • 14
Language
  • English
Version
  • Publisher
ISSN
  • 2234-943X
Publisher
  • Frontiers

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details fonc-14-1325200.pdf 2024-03-04 Public Download